Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Pandoraon Aug 13, 2021 8:56pm
322 Views
Post# 33705397

RE:Competition waiting on FDA approval

RE:Competition waiting on FDA approval
enriquesuave wrote: SESN has been running up lately and now sits at a $1.2 Billion Market Cap now at around $6 per share.  Was around 60-80 cents 12-24 months ago. FDA decision date August 18.  Durable efficacy of 17% CR rate at 12 months mark after 36 instillations of Vicinium.  We need more data, but when we do it will be easy to compare and evaluate what our MC should be.  Hopefully closer to a $Billion than where we are now.  IMO 


SESN closed yesterday at $4.91 and today opened at $5.22 U.S. - hit a high of $6.04 and then a low of $0.70 before closing at $2.11.

Buying at $0.70 might have been good - not sure I would have wanted to be in the other part of it.
The ups and downs of FDA decisions - wow!
<< Previous
Bullboard Posts
Next >>